BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use...
BC Extra | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process  Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its...
BC Extra | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease. According to the company, the data are the first Phase III results...
BC Extra | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's GalXC platform to explore more than 30 liver cell...
Items per page:
1 - 10 of 1060
BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

A ramped up focus on CNS that has been long in the making could start to pay off this year for Roche, which has two programs slated for launch and four others with late-stage readouts...
BC Extra | Jan 8, 2020
Clinical News

Apellis readies to compete with Soliris in PNH based on Phase III data

Apellis’ paroxysmal nocturnal hemoglobinuria candidate has beaten Soliris head-to-head on hemoglobin level improvement. Despite some ambiguity on how FDA will see the data, the company believes pegcetacoplan has a strong case for approval and could...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

After largely being out of biotech stocks for four years, generalist investors have shown signs that they are ready to dip their toes again in 2020. The fourth quarter surge, and a spate of 2019...
BC Extra | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option...
BC Extra | Dec 11, 2019
Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series...
BC Extra | Dec 9, 2019
Company News

Novartis downsizing internal efforts on CAR T in solid tumors

Novartis is pivoting away from internal development of CAR Ts in solid tumors, it said Thursday at its R&D day. The company is, however, pressing forward with the modality via partnerships, and plans to use...
BC Extra | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process  Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its...
BC Extra | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease. According to the company, the data are the first Phase III results...
BC Extra | Nov 18, 2019
Company News

Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna. The partners will use Dicerna's GalXC platform to explore more than 30 liver cell...
Items per page:
1 - 10 of 1060